Carlos Solano

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1814666/publications.pdf

Version: 2024-02-01

176 papers	4,330 citations	126901 33 h-index	138468 58 g-index
177 all docs	177 docs citations	177 times ranked	5031 citing authors

#	Article	IF	Citations
1	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematology,the, 2020, 7, e157-e167.	4.6	319
2	Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stemâ€cell transplantation. British Journal of Haematology, 2011, 155, 318-327.	2.5	205
3	Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. British Journal of Haematology, 2002, 116, 475-482.	2.5	200
4	Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood, 2002, 100, 2243-2245.	1.4	167
5	Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation. JAMA - Journal of the American Medical Association, 2019, 322, 123.	7.4	143
6	Serum Galactomannan Versus a Combination of Galactomannan and Polymerase Chain Reaction-Based Aspergillus DNA Detection for Early Therapy of Invasive Aspergillosis in High-Risk Hematological Patients: A Randomized Controlled Trial. Clinical Infectious Diseases, 2015, 60, 405-414.	5.8	133
7	Quantification of DNA in Plasma by an Automated Real-Time PCR Assay (Cytomegalovirus PCR Kit) for Surveillance of Active Cytomegalovirus Infection and Guidance of Preemptive Therapy for Allogeneic Hematopoietic Stem Cell Transplant Recipients. Journal of Clinical Microbiology, 2008, 46, 3311-3318.	3.9	109
8	Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. British Journal of Haematology, 2001, 115, 653-659.	2.5	102
9	CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors.. Blood, 2007, 110, 461-467.	1.4	82
10	Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. Bone Marrow Transplantation, 2020, 55, 1093-1102.	2.4	78
11	Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers. JAMA Oncology, 2019, 5, 1739.	7.1	76
12	The adjusted International Prognostic Index and Â-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica, 2007, 92, 1067-1074.	3.5	71
13	Uncontrolled immune response in acute myocardial infarction. American Heart Journal, 2008, 156, 1065-1073.	2.7	69
14	Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood, 2002, 100, 724-727.	1.4	68
15	Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica, 2010, 95, 1176-1182.	3.5	63
16	Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyt. British Journal of Haematology, 2001, 114, 931-936.	2.5	60
17	Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach. Biology of Blood and Marrow Transplantation, 2013, 19, 69-74.	2.0	60
18	Diagnostic accuracy and potential clinical value of the LightCycler SeptiFast assay in the management of bloodstream infections occurring in neutropenic and critically ill patients. International Journal of Infectious Diseases, 2011, 15, e326-e331.	3.3	56

#	Article	IF	Citations
19	Enumeration of cytomegalovirus-specific interferonÂ CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection. Haematologica, 2008, 93, 1434-1436.	3.5	49
20	Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study. Cytotherapy, 2017, 19, 927-936.	0.7	49
21	Performance of the QuantiFERON-Cytomegalovirus (CMV) Assay for Detection and Estimation of the Magnitude and Functionality of the CMV-Specific Gamma Interferon-Producing CD8⁺T-Cell Response in Allogeneic Stem Cell Transplant Recipients. Vaccine Journal, 2012, 19, 791-796.	3.1	47
22	GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematology,the, 2019, 6, e89-e99.	4.6	47
23	Comparative Evaluation of Three Automated Systems for DNA Extraction in Conjunction with Three Commercially Available Real-Time PCR Assays for Quantitation of Plasma Cytomegalovirus DNAemia in Allogeneic Stem Cell Transplant Recipients. Journal of Clinical Microbiology, 2011, 49, 2899-2904.	3.9	46
24	Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. BMC Infectious Diseases, 2015, 15, 128.	2.9	46
25	Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple Myeloma. Leukemia and Lymphoma, 2002, 43, 67-75.	1.3	45
26	Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study. Biology of Blood and Marrow Transplantation, 2009, 15, 639-642.	2.0	45
27	Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis. American Journal of Transplantation, 2019, 19, 2479-2494.	4.7	45
28	Dynamics of Torque Teno virus plasma DNAemia in allogeneic stem cell transplant recipients. Journal of Clinical Virology, 2017, 94, 22-28.	3.1	44
29	Comparison of the new Abbott Real Time CMV assay and the Abbott CMV PCR Kit for the quantitation of plasma cytomegalovirus DNAemia. Diagnostic Microbiology and Infectious Disease, 2013, 75, 207-209.	1.8	43
30	SARSâ€CoVâ€2â€reactive interferonâ€Î³â€producing CD8+ T cells in patients hospitalized with coronavirus disease 2019. Journal of Medical Virology, 2021, 93, 375-382.	5.0	43
31	Qualitative Plasma PCR Assay (AMPLICOR CMV Test) versus pp65 Antigenemia Assay for Monitoring Cytomegalovirus Viremia and Guiding Preemptive Ganciclovir Therapy in Allogeneic Stem Cell Transplantation. Journal of Clinical Microbiology, 2001, 39, 3938-3941.	3.9	39
32	Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients. Journal of Medical Virology, 2014, 86, 838-844.	5.0	39
33	Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study. Haematologica, 2009, 94, 1282-1288.	3.5	38
34	Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients. Open Forum Infectious Diseases, 2016, 3, ofw107.	0.9	36
35	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, 358-366.	2.0	36
36	Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source. Biology of Blood and Marrow Transplantation, 2010, 16, 957-966.	2.0	35

#	Article	IF	Citations
37	Dynamics of Cytomegalovirus (CMV) Plasma DNAemia in Initial and Recurrent Episodes of Active CMV Infection in the Allogeneic Stem Cell Transplantation Setting: Implications for Designing Preemptive Antiviral Therapy Strategies. Biology of Blood and Marrow Transplantation, 2011, 17, 1602-1611.	2.0	34
38	An Assessment of the Effect of Human Herpesvirus-6 Replication on Active Cytomegalovirus Infection after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 653-661.	2.0	33
39	An update on the management and prevention of cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. Future Virology, 2015, 10, 113-134.	1.8	33
40	Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. Leukemia and Lymphoma, 2015, 56, 656-662.	1.3	32
41	Positive selection for CD34 + reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Experimental Hematology, 2003, 31, 545-550.	0.4	31
42	Kinetics of cytomegalovirus (CMV) pp65 and IEâ€1â€specific IFNÎ³ CD8⁺ and CD4⁺ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: Potential implications for the management of active CMV infection. Journal of Medical Virology, 2010, 82, 1208-1215.	5.0	31
43	Early Kinetics of Plasma Cytomegalovirus DNA Load in Allogeneic Stem Cell Transplant Recipients in the Era of Highly Sensitive Real-Time PCR Assays: Does It Have Any Clinical Value?. Journal of Clinical Microbiology, 2014, 52, 654-656.	3.9	31
44	Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study. Biology of Blood and Marrow Transplantation, 2018, 24, 563-570.	2.0	31
45	The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate. Haematologica, 2013, 98, 526-532.	3.5	30
46	Frequencies of Blood Group Systems MNS, Diego, and Duffy and Clinical Phases of Carrionâ€™s Disease in Amazonas, Peru. Interdisciplinary Perspectives on Infectious Diseases, 2014, 2014, 1-8.	1.4	30
47	Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study. Bone Marrow Transplantation, 2021, 56, 1171-1179.	2.4	30
48	Clinical virology of cytomegalovirus infection following hematopoietic transplantation. Future Virology, 2010, 5, 111-124.	1.8	29
49	Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting. Journal of General Virology, 2015, 96, 2822-2831.	2.9	29
50	Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. Biology of Blood and Marrow Transplantation, 2016, 22, 1808-1815.	2.0	29
51	Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation. Haematologica, 2014, 99, 1632-1637.	3.5	26
52	Functional profile of cytomegalovirus (CMV)â€specific CD8⁺ T cells and kinetics of NKG2C⁺ NK Cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients. Journal of Medical Virology, 2012, 84, 259-267.	5.0	25
53	A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. Blood Advances, 2018, 2, 1719-1737.	5.2	25
54	Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. Leukemia and Lymphoma, 2009, 50, 216-222.	1.3	24

#	Article	IF	Citations
55	Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8 ⁺ T Cells To Predict CMV DNAemia Clearance in Preemptively Treated Allogeneic Stem Cell Transplant Recipients. Antimicrobial Agents and Chemotherapy, 2014, 58, 5602-5605.	3.2	24
56	Communityâ€acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virusâ€bacterial mixed infections. Transplant Infectious Disease, 2018, 20, e12926.	1.7	24
57	Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transplantation, 2020, 55, 2147-2159.	2.4	24
58	Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. British Journal of Haematology, 2001, 114, 544-550.	2.5	23
59	Immunological Monitoring for Guidance of Preemptive Antiviral Therapy for Active Cytomegalovirus Infection in Allogeneic Stem-Cell Transplant Recipients: A Pilot Experience. Transplantation, 2011, 92, e17-e20.	1.0	22
60	A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation, 2017, 23, 1177-1185.	2.0	22
61	Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation. American Journal of Transplantation, 2018, 18, 2885-2894.	4.7	22
62	An investigation on the relationship between the occurrence of CMV DNAemia and the development of invasive aspergillosis in the allogeneic stem cell transplantation setting. Journal of Medical Virology, 2014, 86, 568-575.	5.0	19
63	Incidence and dynamics of active cytomegalovirus infection in allogeneic stem cell transplant patients according to single nucleotide polymorphisms in donor and recipient CCR5, MCPâ€1, ILâ€10, and TLR9 genes. Journal of Medical Virology, 2015, 87, 248-255.	5.0	19
64	Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of postâ€transplant lymphoproliferative disease. European Journal of Haematology, 2016, 96, 128-135.	2.2	19
65	Kinetics of Alphatorquevirus plasma DNAemia at late times after allogeneic hematopoietic stem cell transplantation. Medical Microbiology and Immunology, 2019, 208, 253-258.	4.8	19
66	Donor CTLA-4 Genotype Influences Clinical Outcome after T Cell-Depleted Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Identical Sibling Donors. Biology of Blood and Marrow Transplantation, 2012, 18, 100-105.	2.0	18
67	Impact of cytomegalovirus <scp>DNA</scp>emia on overall and nonâ€relapse mortality in allogeneic stem cell transplant recipients. Transplant Infectious Disease, 2017, 19, e12717.	1.7	18
68	A riskâ€adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: A pilot study. Transplant Infectious Disease, 2017, 19, e12729.	1.7	17
69	Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients. Transplant Infectious Disease, 2019, 21, e13158.	1.7	17
70	Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia. Journal of Infection, 2019, 78, 393-401.	3.3	17
71	Lack of association between the kinetics of human cytomegalovirus (HCMV) glycoprotein B (gB)-specific and neutralizing serum antibodies and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant. Journal of Medical Virology, 2001, 65, 77-84.	5.0	16
72	Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab. Expert Review of Hematology, 2011, 4, 9-16.	2.2	16

#	Article	IF	Citations
73	Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain. BMC Pharmacology & Toxicology, 2014, 15, 52.	2.4	16
74	Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 1997, 25, 365-372.	1.3	15
75	Cytomegalovirus Infection Management in Allogeneic Stem Cell Transplant Recipients: a National Survey in Spain. Journal of Clinical Microbiology, 2015, 53, 2741-2744.	3.9	15
76	Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or highâ€risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A realâ€world comparison. Mycoses, 2018, 61, 206-212.	4.0	15
77	Kinetics of torque teno virus DNA load in saliva and plasma following allogeneic hematopoietic stem cell transplantation. Journal of Medical Virology, 2018, 90, 1438-1443.	5.0	15
78	Peripheral T-cell lymphoma associated consecutively with hemophagocytic lymphohistiocytosis and hypereosinophilic syndrome. European Journal of Haematology, 2003, 71, 303-306.	2.2	14
79	Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. Bone Marrow Transplantation, 2018, 53, 255-263.	2.4	14
80	A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. EClinicalMedicine, 2021, 33, 100787.	7.1	14
81	Common Genetic Polymorphisms within NFÎºB-Related Genes and the Risk of Developing Invasive Aspergillosis. Frontiers in Microbiology, 2016, 7, 1243.	3.5	13
82	The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey. Bone Marrow Transplantation, 2020, 55, 431-440.	2.4	13
83	Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with postâ€transplantation cyclophosphamide. Transplant Infectious Disease, 2020, 22, e13206.	1.7	13
84	Comparison of the artus Epsteinâ€“Barr virus (EBV) PCR kit and the Abbott RealTime EBV assay for measuring plasma EBV DNA loads in allogeneic stem cell transplant recipients. Diagnostic Microbiology and Infectious Disease, 2017, 88, 36-38.	1.8	12
85	Cytomegalovirus DNAemia Burden and Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation: An Area Under a Curve-Based Investigational Approach. Clinical Infectious Diseases, 2018, 67, 805-807.	5.8	12
86	Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes. Bone Marrow Transplantation, 2019, 54, 90-98.	2.4	12
87	CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review. Current Research in Translational Medicine, 2021, 69, 103304.	1.8	12
88	Differences in cytomegalovirus plasma viral loads measured in allogeneic hematopoietic stem cell transplant recipients using two commercial real-time PCR assays. Journal of Clinical Virology, 2010, 48, 142-146.	3.1	11
89	The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation. PLoS ONE, 2015, 10, e0140454.	2.5	11
90	Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1022-1030.	2.0	11

#	Article	IF	Citations
91	Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies. Biology of Blood and Marrow Transplantation, 2020, 26, 972-977.	2.0	11
92	Amplification of human Î²â€glucuronidase gene for appraising the accuracy of negative SARSâ€CoVâ€2 RTâ€PCR results in upper respiratory tract specimens. Journal of Medical Virology, 2021, 93, 48-50.	5.0	11
93	Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group. American Journal of Transplantation, 2021, 21, 258-271.	4.7	11
94	Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. Annals of Hematology, 2020, 99, 527-537.	1.8	11
95	Reconstitution of lymphocyte populations and cytomegalovirus viremia or disease after allogeneic peripheral blood stem cell transplantation. Journal of Medical Virology, 2003, 70, 399-403.	5.0	10
96	IL28B genetic variation and cytomegalovirusâ€specific Tâ€cell immunity in allogeneic stem cell transplant recipients. Journal of Medical Virology, 2017, 89, 685-695.	5.0	10
97	Hospital and outpatient models for Hematopoietic Stem Cell Transplantation: A systematic review of comparative studies for health outcomes, experience of care and costs. PLoS ONE, 2021, 16, e0254135.	2.5	10
98	The impact of virus population diversity on the dynamics of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. Journal of General Virology, 2017, 98, 2530-2542.	2.9	10
99	Variant Three-Way Translocation of Inversion 16 in AML-M4Eo Confirmed by Fluorescence In Situ Hybridization Analysis. Cancer Genetics and Cytogenetics, 1999, 110, 111-114.	1.0	9
100	Polymyositis after donor lymphocyte infusion. International Journal of Hematology, 2012, 96, 386-389.	1.6	9
101	Would Kinetic Analyses of Plasma Cytomegalovirus DNA Load Help to Reach Consensus Criteria for Triggering the Initiation of Preemptive Antiviral Therapy in Transplant Recipients?: Table 1.. Clinical Infectious Diseases, 2016, 63, 1533-1535.	5.8	9
102	Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?. Journal of Clinical Virology, 2017, 97, 26-32.	3.1	9
103	Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. Bone Marrow Transplantation, 2020, 55, 1347-1356.	2.4	9
104	Prevention of Chronic GvHD after HLA-Identical Sibling Peripheral Hematopietic Stem Cell Transplantation with or without Anti-Lymphocyte Globulin (ATG). Results from a Prospective, Multicenter Randomized Phase III Trial (ATGfamilystudy). Blood, 2014, 124, 37-37.	1.4	9
105	PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation. Annals of Hematology, 2018, 97, 2217-2224.	1.8	8
106	Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain. Future Cardiology, 2018, 14, 3-8.	1.2	8
107	An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. Medical Microbiology and Immunology, 2020, 209, 15-21.	4.8	8
108	Diversity and dynamic changes of anelloviruses in plasma following allogeneic hematopoietic stem cell transplantation. Journal of Medical Virology, 2021, 93, 5167-5172.	5.0	8

#	Article	IF	Citations
109	Thiotepaâ€“busulfanâ€“fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56, 1593-1602.	2.4	8
110	Treatment of Stage I and II Hodgkin's Disease with NOVP (Mitoxantrone, Vincristine, Vinblastine,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.3	7
111	A polymorphism in the TYMP gene is associated with the outcome of HLAâ€identical sibling allogeneic stem cell transplantation. American Journal of Hematology, 2013, 88, 883-889.	4.1	7
112	BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia. Leukemia Research, 2015, 39, 1278-1284.	0.8	7
113	Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. Mycoses, 2017, 60, 79-88.	4.0	7
114	Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease, 2020, 23, e13507.	1.7	7
115	Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease, 2020, 22, e13301.	1.7	7
116	Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. British Journal of Haematology, 2021, 194, 708-717.	2.5	7
117	An XRCC1 polymorphism is associated with the outcome of patients with lymphoma undergoing autologous stem cell transplant. Leukemia and Lymphoma, 2011, 52, 1249-1254.	1.3	6
118	An evaluation of the role of NKG2C⁺ natural killer cells in protection from cytomegalovirus DNAemia early following allogeneic stem cell transplantation. Journal of Medical Virology, 2014, 86, 806-811.	5.0	6
119	Re-examining the relationship between active cytomegalovirus (CMV) infection and acute graft-versus-host disease in allogeneic stem cell transplant recipients in the era of real-time PCR CMV assays. Transplant International, 2016, 29, 126-128.	1.6	6
120	Early adjustment of empirical antibiotic therapy of bloodstream infections on the basis of direct identification of bacteria by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and Gram staining results. Journal of Infection and Chemotherapy, 2020, 26, 963-969.	1.7	6
121	Plasma metabolomics profiling for the prediction of cytomegalovirus DNAemia and analysis of virusâ€“host interaction in allogeneic stem cell transplant recipients. Journal of General Virology, 2015, 96, 3373-3381.	2.9	6
122	Stem-cell transplantation in non-HodgkinÊ¼s lymphoma: improving outcome. Anti-Cancer Drugs, 2002, 13, S35-S42.	1.4	5
123	Enumeration of NKG2C+natural killer cells early following allogeneic stem cell transplant recipients does not allow prediction of the occurrence of cytomegalovirus DNAemia. Journal of Medical Virology, 2015, 87, 1601-1607.	5.0	5
124	Refractory cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation: when should genotypic drug resistance testing be requested?. Bone Marrow Transplantation, 2018, 53, 787-790.	2.4	5
125	Factors influencing cytomegalovirus DNA load measurements in whole blood and plasma specimens from allogeneic hematopoietic stem cell transplant recipients. Diagnostic Microbiology and Infectious Disease, 2019, 94, 22-27.	1.8	5
126	Assessment of the association between cytomegalovirus DNAemia and subsequent acute graftâ€versusâ€host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group. Transplant Infectious Disease, 2021, 23, e13627.	1.7	5

#	Article	IF	Citations
127	A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119). Blood, 2020, 136, 50-51.	1.4	5
128	Polymorphisms within the TNFSF4 and MAPKAPK2 Loci Influence the Risk of Developing Invasive Aspergillosis: A Two-Stage Case Control Study in the Context of the aspBIOmics Consortium. Journal of Fungi (Basel, Switzerland), 2021, 7, 4.	3.5	5
129	Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. Blood Advances, 2022, 6, 848-853.	5.2	5
130	Lack of evidence for a reciprocal interaction between bacterial and cytomegalovirus infection in the allogeneic stem cell transplantation setting. Transplant International, 2016, 29, 1196-1204.	1.6	4
131	Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graftâ€versusâ€host disease following allogeneic hematopoietic stem cell transplantation: Is it of any value?. Transplant Infectious Disease, 2020, 22, e13440.	1.7	4
132	Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graftâ€versusâ€host disease prophylaxis. EJHaem, 2021, 2, 236-248.	1.0	4
133	Cytomegalovirusâ€specific Tâ€cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib. British Journal of Haematology, 2021, 195, 637-641.	2.5	4
134	Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma. Blood, 2020, 136, 19-21.	1.4	4
135	Haploidentical Stem Cell Transplantation (HAPLO-HSCT) With Reduced Intensity Conditioning (RIC) Regimens and High Dose Cylophosphamide Post-Transplant (HD-CY) As Gvhd Prophylaxis In Patients With Relapsed Or Refractory HodgkinÂ´s Disease: Multicentric Spanish Experience. Blood, 2013, 122, 3406-3406.	1.4	4
136	Continuous ambulatory peritoneal dialysis as a promising therapy for light chain amyloidosis with congestive heart failure. International Journal of Cardiology, 2016, 223, 807-809.	1.7	3
137	Monitoring of oral cytomegalovirus DNA shedding for the prediction of viral DNAemia in allogeneic hematopoietic stem cell transplant recipients. Journal of Medical Virology, 2018, 90, 1375-1382.	5.0	3
138	Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples. Anticancer Research, 2019, 39, 4757-4766.	1.1	3
139	Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients. Medical Microbiology and Immunology, 2019, 208, 405-414.	4.8	3
140	Spontaneouslyâ€resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and clinical outcomes. Journal of Medical Virology, 2019, 91, 1128-1135.	5.0	3
141	Assessing the impact on intestinal microbiome and clinical outcomes of antibiotherapy optimisation strategies in haematopoietic stem cell transplant recipients: study protocol for the prospective multicentre OptimBioma study. BMJ Open, 2020, 10, e034570.	1.9	3
142	Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment. Bone Marrow Transplantation, 2021, 56, 1281-1290.	2.4	3
143	Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. Frontiers in Immunology, 2020, 11, 613954.	4.8	3
144	Therapy-related acute myeloid leukemia developing 14â€¯years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H- DNMT3A mutated clone of patient origin. Experimental and Molecular Pathology, 2018, 105, 139-143.	2.1	2

#	Article	IF	Citations
145	Failure of Cytomegalovirus-Specific CD8+ T Cell Levels at Viral DNAemia Onset to Predict the Eventual Need for Preemptive Antiviral Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Journal of Infectious Diseases, 2019, 219, 1510-1512.	4.0	2
146	Clinical significance of Pneumocystis jirovecii DNA detection by real-time PCR in hematological patient respiratory specimens. Journal of Infection, 2020, 80, 578-606.	3.3	2
147	Ex vivo Tâ€cell depletion vs postâ€transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graftâ€vsâ€host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. European Journal of Haematology, 2021, 106, 114-125.	2.2	2
148	Assessing the risk of cytomegalovirus DNAaemia in allogeneic stem cell transplant recipients by monitoring oxidative-stress markers in plasma. Journal of General Virology, 2017, 98, 1855-1863.	2.9	2
149	Validation of a plasma metabolomics model that allows anticipation of the occurrence of cytomegalovirus DNAaemia in allogeneic stem cell transplant recipients. Journal of Medical Microbiology, 2018, 67, 814-819.	1.8	2
150	Low Transplant-Related Mortality in Patients with Hematologic Malignancies Undergoing Umbilical Cord Blood Transplantation (UCBT) with Thiotepa (TT), Once-Daily Intravenous (IV) Busulfan (BU), Fludarabine (FLU) and Anti-Thymocyte Globulin (ATG).. Blood, 2007, 110, 618-618.	1.4	2
151	The FLIPI2 SCORE Predicts PROGRESSION-FREE SURVIVAL (PFS) and OVERALL SURVIVAL (OS) IN AN INDEPENDENT SERIES of Follicular LYMPHOMA: A Single Institution EXPERIENCE. Blood, 2010, 116, 3128-3128.	1.4	2
152	Peripheral blood regulatory T cells and occurrence of Cytomegalovirus DNAemia after unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. Bone Marrow Transplantation, 2020, 55, 1493-1496.	2.4	2
153	Effect of Cytomegalovirus (CMV) Serostatus on the Incidence and Virological Features of Active CMV Infection in Allogeneic Stem Cell Transplant Recipients. Clinical Infectious Diseases, 2011, 53, 313-315.	5.8	1
154	Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. Leukemia and Lymphoma, 2020, 61, 1823-1832.	1.3	1
155	Prospective Study of Oral Valganciclovir for Pre-Emptive Therapy of Cytomegalovirus After Allogeneic Stem Cell Transplantation.. Blood, 2009, 114, 1168-1168.	1.4	1
156	Outcomes In Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation Using Intravenous Busulfan and Melphalan: A Matched Comparison to a Double Autologous Transplant Strategy. Blood, 2010, 116, 3560-3560.	1.4	1
157	Donor and Recipient Genotypes for Interleukin 1 Gene Single Nucleotide Polymorphisms (SNPs) Allow Anticipation of Acute Graft Versus Host Disease after HLA-Identical Allogeneic Stem Cell Transplantation (allo-SCT). Blood, 2014, 124, 666-666.	1.4	1
158	Are Outcomes After Myeloablative Conditioning Regimen in Double Cord Blood Transplantation (UCBT) Better Than Single UCBT for Adults with Acute Leukemia in Remission?. Biology of Blood and Marrow Transplantation, 2013, 19, S126.	2.0	0
159	Active cytomegalovirus infection is not a risk factor for <scp>E</scp>psteinâ€“<scp>B</scp>arr virus <scp>DNA</scp>emia in the allogeneic stem cell transplantation setting. Clinical Transplantation, 2014, 28, 508-511.	1.6	0
160	Haploidentical Stem Cell Transplantation (HAPLO-HSCT) with Post-Transplant Cyclophosphamide (PT-CY) As Gvhd Prophylaxis in High Risk Hematologic Malignancies: Bone Marrow or Peripheral Blood Progenitors Render Same Results. Biology of Blood and Marrow Transplantation, 2015, 21, S284.	2.0	0
161	How to best manage cytomegalovirus infection in the allogeneic stem cell transplant setting: future prospects. Future Virology, 2016, 11, 603-606.	1.8	0
162	Cytomegalovirus DNAemia in patients with de novo acute myeloid leukemia undergoing cytotoxic chemotherapy. Leukemia and Lymphoma, 2019, 60, 3081-3083.	1.3	0

#	Article	IF	Citations
163	Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2019, 54, 1133-1137.	2.4	0
164	Toxicity and Early Response after Single Daily Dose of Intravenous Busulfan and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma.. Blood, 2007, 110, 4928-4928.	1.4	0
165	Assessment of the Impact of Human Herpesvirus 6 (HHV-6) Replication On Active Citomegalovirus (CMV) Infection After Allogeneic Stem Cell Transplantation (Allo-SCT).. Blood, 2009, 114, 2225-2225.	1.4	0
166	The Genotype of the Donor for the Polymorphism A7488G of the IL-17 Gene Influences relapse and survival After HLA-Identical Related Stem Cell Transplantation.. Blood, 2010, 116, 1302-1302.	1.4	0
167	Graft-Failure After Allogeneic Stem Cell Transplantation. Outcome and Prognostic Factors in 80 Patients. Blood, 2011, 118, 1936-1936.	1.4	0
168	The Combination of Siromilus Plus Tacrolimus (SiTac) Improves the Results of Cyclosporine Plus Mycophenolate Mofetil (CsAMMF) After Reduced Intensity Conditioning (RIC) Unrelated Donor Allogeneic Transplantation. Blood, 2011, 118, 890-890.	1.4	0
169	Outcome of Second Allogeneic SCT Following Relapse of Hematological Malignancies After a First Allogeneic SCT. Blood, 2011, 118, 3056-3056.	1.4	0
170	The Genotype in the Donor and Recipient for the Polymorphim â^'174 G/C of the IL-6 Influences the Outcome of HLA-Identical Related Stem Cell Transplantation,. Blood, 2011, 118, 4082-4082.	1.4	0
171	Vascular Endothelial Growth Factor (VEGF) Increases B-CLL CELL Migration Through Regulation of CXCR4/SDF1 AXIS. Blood, 2012, 120, 3917-3917.	1.4	0
172	Are Outcomes After Myeloablative Conditioning Regimen in Double Cord Blood Transplantation (UCBT) Better Than Single UCBT for Adults with Acute Leukemia in Remission?.. Blood, 2012, 120, 3083-3083.	1.4	0
173	Haploidentical Stem Cell Transplantation (HAPLO-HSCT) With High Dose Cyclophosphamide Post-Transplant (HD-CY) As Gvhd Prophylaxis In High Risk Hematologic Malignancies: Multicentric Spanish Experience. Blood, 2013, 122, 2173-2173.	1.4	0
174	Vegf and bFGF Single-Nucleotide Polymorphisms In Chronic Lymphocytic Leukemia: Impact On Susceptibility. Blood, 2013, 122, 5287-5287.	1.4	0
175	Strategies for Graft Versus Host Disease Prophylaxis after Reduced-Intensity Conditioning Transplantation: Combination of Sirolimus Plus Tacrolimus Allows to Obtain the Best Outcome. Blood, 2014, 124, 1165-1165.	1.4	0
176	Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants. Journal of Health Economics and Outcomes Research, 2015, 3, 153-161.	1.2	0